CASI Pharmaceuticals focuses on building a pipeline through mutually beneficial business development transactions. The Company's strategy leverages its resources and expertise in China to develop and commercialize innovative products in China and other markets.
Type
Public
HQ
Rockville, US
Founded
1991
Size (employees)
26 (est)+30%
CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, US
Report incorrect company information

Key People/Management at CASI Pharmaceuticals

Sara Capitelli

Sara Capitelli

Vice President, Finance and Principal Accounting Officer

CASI Pharmaceuticals Office Locations

CASI Pharmaceuticals has offices in Rockville and Beijing
Rockville, US (HQ)
300 9620 Medical Center Dr
Beijing, CN
CASI (Beijing) Pharmaceuticals, Inc. FullLink Plaza Suite B1214, B1215 18 Chaoyangmenwai Street, Chaoyang
Show all (2)
Report incorrect company information

CASI Pharmaceuticals Financials and Metrics

CASI Pharmaceuticals Revenue

CASI Pharmaceuticals's revenue was reported to be $47.71 k in FY, 2015 which is a 101.1% increase from the previous period.
USD

Net income (Q1, 2018)

(3.6 m)

Market capitalization (18-Jul-2018)

621.1 m

Closing share price (18-Jul-2018)

7.2

Cash (31-Mar-2018)

49.9 m

EV

572.7 m
CASI Pharmaceuticals's current market capitalization is $621.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.7 k47.7 k

Revenue growth, %

101%

Cost of goods sold

7.5 k6.3 k

Gross profit

16.3 k41.4 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cost of goods sold

6.3 k2.7 k

General and administrative expense

648.7 k891.4 k891.9 k1.2 m924.8 k857.6 k673.9 k765.1 k1.9 m676.9 k644.2 k691.4 k625.9 k1.3 m

R&D expense

793.8 k560 k724.5 k697 k865 k1.2 m942.3 k1 m1.4 m1 m1 m1.7 m971 k1.7 m

Operating expense total

1.4 m1.5 m1.6 m1.8 m1.8 m2.1 m1.6 m1.8 m3.3 m1.7 m1.7 m2.4 m1.6 m3 m
Annual
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

6.3 m4.9 m1.1 m8 m15.1 m10.7 m5.1 m27.1 m

Accounts Receivable

Inventories

Current Assets

15.4 m11 m5.6 m27.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

15.9 m14.2 m13.1 m11.8 m9.5 m8 m6.4 m13.9 m18.5 m24.1 m25.5 m23.4 m21.6 m49.9 m

Current Assets

16.2 m14.5 m13.2 m12.2 m9.9 m8.3 m6.8 m14.3 m18.8 m24.5 m25.9 m23.6 m22.1 m52.1 m

PP&E

56.6 k113.7 k240.4 k230.6 k246.3 k245.3 k234.7 k222.8 k168.7 k184.1 k244.6 k448.5 k566 k1.2 m

Total Assets

16.3 m14.6 m13.5 m12.4 m10.2 m8.6 m7.1 m14.5 m19 m24.8 m26.2 m24.1 m22.7 m71.2 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(26.2 m)(7.2 m)(9.5 m)

Depreciation and Amortization

48.2 k68.4 k66.5 k

Inventories

Accounts Payable

352.2 k129.5 k180.5 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.4 m)(1.5 m)(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)(3.6 m)

Depreciation and Amortization

12.9 k6.5 k19.2 k32.7 k65.8 k

Accounts Payable

(152.6 k)189.3 k171.1 k197.8 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m(522.3 k)

Cash From Operating Activities

(2.6 m)(890.1 k)(1.9 m)(2.9 m)(5.4 m)
USDY, 2018

EV/CFO

-106 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

CASI Pharmaceuticals Company Life and Culture

Report incorrect company information